Directorio de personas
Nuria Eritja Sanchez

Nuria Eritja Sanchez

Grado: Doctor/a

973 70 29 37
neritja(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/M-1347-2015

Grupos

Publicaciones

  • Alberti-Valls, M; Olave, S; Olomí, A; Macià, A; Eritja, N

    Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment

    Cancers 16 -. .

    [doi:10.3390/cancers16233918]

  • Albertí-Valls M; Megino-Luque C; Macià A; Gatius S; Matias-Guiu X; Eritja N

    Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review.

    Cancers 16 -. .

    [doi:10.3390/cancers16010185]

  • Sonzini, Giorgia; Granados-Aparici, Sofia; Sanegre, Sabina; Diaz-Lagares, Angel; Diaz-Martin, Juan; de Andrea, Carlos; Eritja, Nuria; Bao-Caamano, Aida; Costa-Fraga, Nicolas; Garcia-Ros, David; Salguero-Aranda, Carmen; Davidson, Ben; Lopez-Lopez, Rafael; Melero, Ignacio; Navarro, Samuel; Ramon Y Cajal, Santiago; de Alava, Enrique; Matias-Guiu, Xavier; Noguera, Rosa

    Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness.

    Frontiers In Cell And Developmental Biology 10 1052098-1052098. .

    [doi:10.3389/fcell.2022.1052098]

  • Barcelo, C.; Siso, P.; de la Rosa, I.; Megino-Luque, C.; Navaridas, R.; Maiques, O.; Urdanibia, I.; Eritja, N.; Soria, X.; Potrony, M.; Calbet-Llopart, N.; Puig, S.; Matias-Guiu, X.; Marti, R. M.; Macia, A.

    M-CSF as a therapeutic target in BRAF(V600E) melanoma resistant to BRAF inhibitors.

    BRITISH JOURNAL OF CANCER 127 1142-1152. .

    [doi:10.1038/s41416-022-01886-4]

  • Ruiz-Mitjana, A; Navaridas, R; Vidal-Sabanes, M; Perramon-Guell, A; Yeramian, A; Felip, I; Eritja, N; Egea, J; Encinas, M; Matias-Guiu, X; Dolcet, X

    Lack of extracellular matrix switches TGF-ß induced apoptosis of endometrial cells to epithelial to mesenchymal transition.

    SCIENTIFIC REPORTS 12 14821-14821. .

    [doi:10.1038/s41598-022-18976-1]

  • Gatius S; Jove M; Megino-Luque C; Albertí-Valls M; Yeramian A; Bonifaci N; Piñol M; Santacana M; Pradas I; Llobet-Navas D; Pamplona R; Matías-Guiu X; Eritja N

    Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer.

    Cancers 14 -. .

    [doi:10.3390/cancers14122842]

  • Megino-Luque, Cristina; Siso, Pol; Mota-Martorell, Natalia; Navaridas, Raul; de la Rosa I; Urdanibia, Izaskun; Alberti-Valls, Manel; Santacana, Maria; Pinyol, Miquel; Bonifaci, Nuria; Macia, Anna; Llobet-Navas, David; Gatius, Sonia; Matias-Guiu, Xavier; Eritja, Nuria

    ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.

    MOLECULAR ONCOLOGY 16 2235-2259. .

    [doi:10.1002/1878-0261.13193]

  • Eritja N; Navaridas R; Ruiz-Mitjana A; Vidal-Sabanés M; Egea J; Encinas M; Matias-Guiu X; Dolcet X

    Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation

    Cancers 13 -. .

    [doi:10.3390/cancers13194990]

  • Sanegre S; Eritja N; de Andrea C; Diaz-Martin J; Diaz-Lagares Á; Jácome MA; Salguero-Aranda C; García Ros D; Davidson B; Lopez R; Melero I; Navarro S; Ramon Y Cajal S; de Alava E; Matias-Guiu X; Noguera R

    Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma.

    Frontiers In Cell And Developmental Biology 9 670185-670185. .

    [doi:10.3389/fcell.2021.670185]

  • Megino-Luque C; Moiola CP; Molins-Escuder C; López-Gil C; Gil-Moreno A; Matias-Guiu X; Colas E; Eritja N

    Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

    Cancers 12 1-26. .

    [doi:10.3390/cancers12102751]

  • Cuevas, D; Velasco, A; Vaquero, M; Santacana, M; Gatius, S; Eritja, N; Estaran, E; Matias-Guiu, X

    Intratumor heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification (MLPA). A DESCRIPTIVE STUDY.

    Histopathology 76 447-460. .

    [doi:10.1111/his.14001]

  • Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet, X; Matias-Guiu, X; Marti, RM; Macia, A

    T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF V600E melanoma: TTCCs are therapy target in BRAF V600E melanoma.

    JOURNAL OF INVESTIGATIVE DERMATOLOGY 140 1253-1265. .

    [doi:10.1016/j.jid.2019.11.014]

Proyectos

  • Estudio de los efectos de la inhibición de la vía PI3K/AKT/mTOR en tumores deficientes en PTEN: mecanismos de resisitencia y nuevas estrategias terapéuticas
  • UNA FLOR PER A UN PROJECTE: ESTUDI DE DOS FARMACS PEL TRACTAMENT DEL MELANOMA
  • MECANISMOS DE REGULACION FLIP Y LA RESPUESTA A TRAIL EN EL DESARROLLO Y PROGRESION DEL CANCER
  • Caracterización de las células neoplásicas inmaduras pluripotenciales (células madre neoplásicas) en el cáncer de endometrio. Implicaciones Patogénicas, pronósticas y terapeuticas
  • AYUDAS PREDOCTORALES DE FORMACION EN INVESTIGACION EN SALUD
  • Unravelling the molecular and phenotypic complexity of endometriosis through new models and omics integration: towards a personalized clinical management